Resistance to antimony and treatment failure in human Leishmania (Viannia) infection

Background. Failure of antimonial therapy has been increasingly reported in anthroponotic visceral leishmaniasis and in cutaneous disease. The role of drug resistance in treatment failure has been difficult to ascertain because therapeutic response is multifactorial, and the efficacy of antimonial drugs depends on an effective immune response. In this study, we sought to determine whether standard treatment selects for resistant organisms and whether drug resistance contributes to treatment failure. Methods. We evaluated the susceptibility to antimony of 19 strains isolated before treatment with meglumine antimoniate and 21 strains isolated at treatment failure from 20 patients. The 50% effective dose ( ED50) of antimony in the form of additive-free meglumine antimoniate was determined for intracellular amastigotes in human promonocytic U-937 cells. Results. Before treatment, 16% of strains ( 3/19) showed primary resistance ( ED50 of 1128 mu g Sb/mL), whereas 84% ( 16/19) were susceptible ( ED50 of < 20 mu g Sb/mL). However, 88% of susceptible strains ( 14/16) had ED90 values of > 128 mu g Sb/mL. At treatment failure, 40% of strains ( 8/20) were resistant. Secondary resistance was documented in 4 patients. Conclusions. Primary and secondary resistance to antimony can contribute to treatment failure in American cutaneous leishmaniasis. Selection for resistance to antimony occurs during standard treatment with antimonial drugs, and primary resistance to antimony supports the plausibility of anthroponotic transmission.